Top

Published in:

01-04-2015 | Editorial

Note of clarification of data in the paper entitled no association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis

Authors: Haiyan Yang, Fuye Shao, Haiyu Wang, Yadong Wang

Published in: Tumor Biology | Issue 4/2015

Excerpt

We read with great interest the paper entitled “No association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis” published in Tumor Biol. 2014, 35: 5629–5635 [1]. Zhang et al. performed a meta-analysis to explore the association between X-ray repair cross-complementing group 1 (XRCC1) Arg194Trp polymorphism and lung cancer risk on the basis of 25 case-control studies with 8876 cases and 11,210 controls. The authors found that XRCC1 Arg194Trp polymorphism was not associated with lung cancer risk [odds ratio (OR) = 0.97 with 95 % confidence interval (95 %CI): 0.92–1.03 for Trp vs. Arg; OR = 0.92 with 95 %CI: 0.85–0.98 for Arg/Trp vs. Arg/Arg; OR = 1.07 with 95 %CI: 0.92–1.23 for Trp/Trp vs. Arg/Arg; OR = 0.93 with 95 %CI: 0.87–1.00 for Trp/Trp + Arg/Trp vs. Arg/Arg; and OR = 1.08 with 95 %CI: 0.94–1.25 for Trp/Trp vs. Arg/Trp + Arg/Arg]. The cumulative meta-analysis showed that the results maintained the same, while the ORs with 95 % CI were more stable with the accumulation of case-control studies. It is a valuable study. …

Zhang J, Zeng XT, Lei JR, Tang YJ, Yang J. No association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis. Tumour Biol. 2014;35:5629–35.CrossRefPubMedPubMedCentral

Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D, et al. DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res. 2006;66:11062–9.CrossRefPubMed

Wang N, Wu Y, Zhou X. Association between genetic polymorphism of metabolizing enzymes and DNA repairing enzymes and the susceptibility of lung cancer in Henan population. Wei Sheng Yan Jiu. 2012;41:251–6.PubMed

Song Y, Yin L, Pu Y, Liang G, Cui H. Relationship between polymorphisms of DNA repair gene XRCC1 and susceptibility to lung cancer in Nanjing population. J Labour Med. 2004;21:18–21.

Du Y, He Y, Mei Z, Qian L, Shi J, Jie Z. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population. Clin Respir J. 2014. doi:10.1111/crj.12218.PubMed

Buch SC, Diergaarde B, Nukui T, Day RS, Siegfried JM, Romkes M, et al. Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Mol Carcinog. 2012;51 Suppl 1:E11–20.CrossRefPubMed

Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet. 2005;162:10–20.CrossRefPubMed

Chang JS, Wrensch MR, Hansen HM, Sison JD, Aldrich MC, Quesenberry Jr CP, et al. Base excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African-Americans. Carcinogenesis. 2009;30:78–87.CrossRefPubMed

Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002;23:1321–5.CrossRefPubMed

10.

David-Beabes GL, London SJ. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer. 2001;34:333–9.CrossRefPubMed

11.

De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101–10.CrossRefPubMed

12.

Du Y, Chu DJ, Shi JM, Fan W. The relationship between lung cancer and genetic polymorphism of XRCC1. J Clin Intern Med. 2012;29:346–8.

13.

Guo S, Li X, Gao M, Li Y, Song B, Niu W. The relationship between XRCC1 and XRCC3 gene polymorphisms and lung cancer risk in northeastern Chinese. PLoS One. 2013;8:e56213.CrossRefPubMedPubMedCentral

14.

Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene. 2006;25:3613–20.CrossRefPubMed

15.

Hu Z, Ma H, Lu D, Zhou J, Chen Y, Xu L, et al. A promoter polymorphism (-77T > C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics. 2005;15:457–63.CrossRefPubMed

16.

Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005;97:567–76.CrossRefPubMed

17.

Improta G, Sgambato A, Bianchino G, Zupa A, Grieco V, La Torre G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population. Anticancer Res. 2008;28:2941–6.PubMed

18.

Janik J, Swoboda M, Janowska B, Ciesla JM, Gackowski D, Kowalewski J, et al. 8-Oxoguanine incision activity is impaired in lung tissues of NSCLC patients with the polymorphism of OGG1 and XRCC1 genes. Mutat Res. 2011;709–710:21–31.CrossRefPubMed

19.

Li M, Yin Z, Guan P, Li X, Cui Z, Zhang J, et al. XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer. 2008;62:145–51.CrossRefPubMed

20.

Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006;27:997–1007.CrossRefPubMed

21.

Pachouri SS, Sobti RC, Kaur P, Singh J. Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in the north-Indian population. DNA Cell Biol. 2007;26:186–91.CrossRefPubMed

22.

Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:119–23.PubMed

23.

Schneider J, Classen V, Bernges U, Philipp M. XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking. Int J Mol Med. 2005;16:709–16.PubMed

24.

Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei. China Anticancer Res. 2005;25:537–42.PubMed

25.

Su J, Niu RG, Han XY, Shi JP, Liu L, Li JW, et al. Polymorphisms of DNA repair gene XRCC1 codon194 and its susceptibility to lung cancer. Fudan Univ J Med Sci. 2008;35:348–52.

26.

Tanaka Y, Maniwa Y, Bermudez VP, Doi T, Nishio W, Ohbayashi C. Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk. Cancer. 2010;116:896–902.CrossRefPubMed

27.

Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.CrossRefPubMed

28.

Yu H, Zeng X, Chou X, Xu S, Shi L, Zhang X, et al. Polymorphism in the DNA repair gene XRCC1 and susceptibility to human lung cancer. J Guangxi Med University. 2006;23:355–8.

29.

Zhang W, Wu Y, Wu Y. Study on polymorphism of XRCC1 and susceptibility to lung cancer. China Public Health. 2005;5:561–3.

30.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27:560–7.CrossRefPubMed

Title: Note of clarification of data in the paper entitled no association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis
Authors: Haiyan Yang
Fuye Shao
Haiyu Wang
Yadong Wang
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3234-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2015

Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma

Knockdown of autophagy-related protein 6, Beclin-1, decreases cell growth, invasion, and metastasis and has a positive effect on chemotherapy-induced cytotoxicity in osteosarcoma cells

Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression

Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma

Overexpression of Numb suppresses growth, migration, and invasion of human clear cell renal cell carcinoma cells

Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer